Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04132830 · ClinicalTrials.gov registry record
HIV Exposure in Utero and Metabolic Disease Risk in HIV-Negative Young Adults
A clinical trial, sponsored by Massachusetts General Hospital.
- Completed
- Registry status
- 174
- Enrollment target
NCT04132830: Completed study, sponsored by Massachusetts General Hospital.
NCT04132830 is a clinical trial that has completed, run by Massachusetts General Hospital. The registered enrollment target is 174 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04132830 has completed, sponsored by Massachusetts General Hospital.
- COMPLETED
- Registry status
- 174 participants
- Enrollment target
Study Summary
Globally, over 1 million babies are born to mothers with HIV each year. With the advent of prenatal antiretroviral therapy, up to 98% of these individuals may be HIV-exposed uninfected (HEU). A growing literature suggests that in utero HIV exposure - even in the absence of subsequent infection - may be associated with adverse health outcomes in infancy and childhood. However, there is little information about the long-term health implications of in utero HIV exposure later in life, such as into adulthood. In this study, for the first time, we seek to prospectively evaluate metabolic and immune indices among HEU young adults as compared to well-matched HIV-unexposed uninfected controls. This study serves as a necessary first step toward optimizing clinical care for this expanding and aging HEU population, including the implementation of novel screening and prevention strategies.
Interventions
- OTHER In Utero HIV Exposure
- OTHER No In Utero HIV Exposure
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 174 participants |
| Start Date | 2019-10-01 |
| Est. Completion | 2024-07-26 |
What the finished NCT04132830 record still lists
NCT04132830 is an observational study that tracks outcomes without assigning an intervention. The registered 174 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 2 interventions - of which In Utero HIV Exposure is the first listed.
NCT04132830 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04132830 about?
NCT04132830 is a clinical study titled "HIV Exposure in Utero and Metabolic Disease Risk in HIV-Negative Young Adults". Globally, over 1 million babies are born to mothers with HIV each year. With the advent of prenatal antiretroviral therapy, up to 98% of these individuals may be HIV-exposed uninfected (HEU). A growing literature suggests that in utero HIV exposure - even in the absence of subsequent infection - may...
What is the current status of trial NCT04132830?
This trial is currently completed. The enrollment target is 174 participants. The study started on 2019-10-01. Estimated completion is 2024-07-26.
What interventions are being tested in trial NCT04132830?
The interventions under investigation include: In Utero HIV Exposure (OTHER), No In Utero HIV Exposure (OTHER).
Who is sponsoring clinical trial NCT04132830?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01000259 · 174 participants
Study of Tumor Tissue Samples From Patients Who Have Undergone Surgery for Advanced Stage III or Stage IV Ovarian Epithelial Cancer
- NCT04729114 · 174 participants · Phase 1
A Safety and Dose-finding Study of PRL-02 Depot in Men With Advanced Prostate Cancer
- NCT04884035 · 174 participants · Phase 1
Study of Safety and Efficacy of Iberdomide (CC-220) and CC-99282 Combined With R-CHOP to Treat Lymphoma
- NCT05075980 · 174 participants · Phase 2
Intensity Modulated Proton or X-Ray Therapy After Surgery for Treatment of Head and Neck Cancer, the HEADLIGHT Study
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI